We Claim:

1. A pharmaceutical composition for topical administration providing an enhanced localization of active ingredient comprising of at least one active ingredient, its salts, esters, hydrates or derivatives; a gelator system consisting of a blend of surfactants, a solvent system comprising at least one oily component; an aqueous phase comprising one or more stabilizing agent; and optionally other pharmaceutically acceptable excipients; wherein the blend of surfactants act as gelators of the oily component present in the solvent system forming a three dimensional network which immobilize the solvent system characterized such that the surfactant gelled oily phase can accommodate the aqueous phase without changing the lipid microenvironment and gel architecture of the composition.

2. A pharmaceutical composition, according to claim 1, wherein the active ingredient is either hydrophobic or amphiphilic in nature.

3. A pharmaceutical composition according to claim 1, wherein the active ingredient is selected from a group comprising antifungals, antibacterials, immunomodulators, steroids, analgesics, anti-inflammatory agents, keratinizing agents, antimicrobials, skin nourishing or sensitizing agents, anti-psoriatic and anti-eczema drugs, used either alone or in combination thereof.

4. A pharmaceutical composition according to claim 3, wherein the active ingredient is terbinafine, its salts, esters, hydrates or derivatives thereof.

5. A pharmaceutical composition according to claim 3, wherein the active ingredient is an immunomodulator selected from tacrolimus or cyclosporine, or salts, esters, hydrates or derivatives thereof.

6. A pharmaceutical composition according to claim 3, wherein the active ingredient is a steroid selected from testosterone or hydrocortisone or salts, esters, hydrates or derivatives thereof.

7. A pharmaceutical composition according to claims 1-6, where the gelator system consisting of a blend of surfactants comprise of at least two surfactants

wherein at least one is a hydrophilic surfactant having an HLB value greater than or equal to about 10; and a lipophilic surfactant having an HLB value less than about 10, said lipophilic surfactant component being present in an amount sufficient to achieve the required concentration ratio of the blend of surfactants to bring about the gelation of one or more oily components present in the solvent system.

8. A pharmaceutical composition according to claims 1-7, wherein the gelator system consisting of a blend of surfactants comprises at least two surfactants wherein both the surfactants are non-ionic.

9. A pharmaceutical composition according to claims 1-8, wherein the gelator system is present in an amount from about 5 % to about 50 % by weight of the total weight of composition.

10. A pharmaceutical composition according to claims 1-9, wherein the hydrophilic surfactant is selected from a group comprising polyoxyethylene sorbitan fatty acid esters, sodium docusate, succinylated monoglycerides, lauryl sulfates, taurocholates, caprylates, caprates, oleates, poloxamer, or mixtures thereof.

11. A pharmaceutical composition according to claims 1-9, wherein the lipophilic surfactant is selected from a group comprising sorbitan fatty acid esters, polyoxyethylene alkylethers, fatty acid esters, polyoxyethylene glycerides, transesterified vegetable oils, polyoxyethylene hydrogenated vegetable oils, or mixtures thereof.

12. A pharmaceutical composition according to claims 1-9, wherein the gelator system consisting of a blend of surfactants comprise a lipophilic surfactant which is a sorbitan fatty acid ester selected from a group comprising sorbitan monolaurate, sorbitan monopalmitate, sorbitan monooleate, and sorbitan monostearate; and a hydrophilic surfactant which is a polyoxyethylene sorbitan fatty acid ester selected from a group comprising polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monooleate, and polyoxyethylene sorbitan monostearate.

13. A pharmaceutical composition according to claims 7-12, wherein the ratio of hydrophilic surfactant to lipophilic surfactant is about 1:20 to about 20:1.

14. A pharmaceutical composition according to claim 1, wherein the solvent system comprises at least one oily component, and one or more other components selected from a group comprising methanol, ethanol, isopropanol, triethyl citrate, acetyl butyl citrate or triacetin; or other hydrophilic solvents selected from a group comprising ethylene glycol, propylene glycol, glycerol, polyethylene glycol, and polyethylene glycol esters.

15. A pharmaceutical composition according to claim 14, wherein the at least one oily component of the solvent system is selected from a group comprising natural oils, mineral oil, mono-, di-, or tri-glyceride esters of oils selected from a group consisting of medium chain triglycerides, oleic acid, ethyl oleate, ethyl caprylate, ethyl butyrate, isopropyl myristate, soyabean oil, canola oil or their mono-and di-glycerides, aluminium monomonostearate, aluminium dimonostearate, aluminium trimonostearate, microcrystalline wax, petroleum wax and mixtures, used either alone or in combination thereof.

16. A pharmaceutical composition according to claims 14 and 15, wherein the at least one oily component of the solvent system is a medium chain triglyceride.

17. A pharmaceutical composition according to claim 1, wherein the aqueous phase comprises water, aliphatic or aromatic alcohols, glycols, or mixtures thereof.

18. A pharmaceutical composition according to claim 1, wherein the stabilizing agent is a natural, synthetic, or semisynthetic polymer which act as structure-former and stabilizer in the topical formulations which range from an emulsion, cream, lotion or gel in their consistency and architecture, selected from a group comprising chitosan, poloxamer, cellulosic polymers, gums and alginates.

19. A pharmaceutical composition according to claim 18, wherein the stabilizing agent is poloxamer.

20. A pharmaceutical composition according to claims 18 and 19, wherein the stabilizer is added either in the oily phase or in aqueous phase or added as an aqueous solution up to about a concentration ranging from 0.1% to 20% of the total weight of the composition.

21. A pharmaceutical composition according to claim 1, wherein the other pharmaceutically acceptable excipients are selected from a the group comprising of preservatives, formulation aids, antioxidants, diluents, pH adjusting agents, buffering agents, tonicity modifiers, colorants, and the like, or mixtures there of.

22. A process for the preparation of a pharmaceutical composition according to claim 1, which comprises of the following steps:

i). preparation of the oily phase comprising gelator system,
ii). incorporating the active ingredient(s) into the oily phase,
iii). preparation of the aqueous phase comprising stabilizer,
iv). mixing both the oily phase and the aqueous phase with continuous stirring to obtain the desired composition.

23. A method for the treatment of fungal, bacterial or microbial infections, inflammations, autoimmune conditions, or hormonal disorders comprising administering a pharmaceutically effective amount of a pharmaceutical composition according to claim 1 to a subject in need of such treatment.

24. The pharmaceutical composition substantially as herein described and illustrated by the examples.

25. The process for the preparation of a pharmaceutical composition substantially as herein described and illustrated by the examples.